Barclays PLC Biodesix Inc Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Biodesix Inc stock. As of the latest transaction made, Barclays PLC holds 180 shares of BDSX stock, worth $73. This represents 0.0% of its overall portfolio holdings.

Number of Shares

180

Previous 180 -0.0%

Holding current value

$73

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$0.22 - $0.63 $12,156 - $34,811	-55,256 Reduced 99.68%	180 $0
Q1 2025 May 15, 2025	SELL	$0.63 - $1.52 $35,795 - $86,363	-56,818 Reduced 50.62%	55,436 $35,000
Q4 2024 Feb 13, 2025	BUY	$1.16 - $1.76 $103,492 - $157,023	89,218 Added 387.3%	112,254 $171,000
Q3 2024 Nov 15, 2024	BUY	$1.53 - $1.96 $32,403 - $41,510	21,179 Added 1140.5%	23,036 $41,000
Q2 2024 Aug 14, 2024	SELL	$1.21 - $1.71 $8,995 - $12,712	-7,434 Reduced 80.01%	1,857 $3,000
Q4 2023 Feb 15, 2024	BUY	$1.2 - $2.13 $11,149 - $19,789	9,291 New	9,291 $17,000
Q2 2023 Aug 03, 2023	BUY	$1.12 - $1.88 $276 - $464	247 New	247 $0
Q2 2022 Aug 12, 2022	SELL	$1.32 - $2.12 $3,016 - $4,844	-2,285 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.69 - $5.81 $3,861 - $13,275	2,285 New	2,285 $4,000

Others Institutions Holding BDSX

# of Institutions

Shares Held

35.8M

Call Options Held

Put Options Held

Telemark Asset Management, LLC Boston, MA

8.28M
Shares

$3.4 Million
0.75% of portfolio
Bryn Mawr Trust CO Bryn Mawr, PA

6.1M
Shares

$2.5 Million
0.03% of portfolio
Birchview Capital, LP Burlington, VT

5.74M
Shares

$2.35 Million
1.69% of portfolio
Vanguard Group Inc Valley Forge, PA

3.79M
Shares

$1.56 Million
0.0% of portfolio
Perceptive Advisors LLC New York, NY

2.17M
Shares

$891,290
0.03% of portfolio

View Full List

About BIODESIX INC

Ticker BDSX
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 39,982,000
Market Cap $16.4M
Description
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...

More about BDSX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account